Elevated Serum Tryptase and Endothelin in Patients with ST Segment Elevation Myocardial Infarction: Preliminary Report

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2015 Jun 20

PMID 26089601

Citations 5

Authors

Lukasz Lewicki

Janusz Siebert

Natalia Marek-Trzonkowska

Emilia Masiewicz

Tomasz Kolinski

Magdalena Reiwer-Gostomska

Radoslaw Targonski

Piotr Trzonkowski

Affiliations

Soon will be listed here.

Abstract

Unlabelled: An inflammatory response plays a crucial role in myocardial damage after an acute myocardial infarction.

Objectives: To measure serum concentrations of several mediators in patients with an acute myocardial infarction (STEMI) and to assess their potential relationship with a risk of coronary instability.

Patients And Methods: The 33 patients with STEMI and 19 healthy volunteers were analyzed. The clinical data were obtained; as well serum concentrations of tryptase, endothelin (ET-1), angiogenin, soluble c-kit, and PDGF were measured.

Results: Patients with STEMI had higher serum tryptase and ET-1 than healthy volunteers (2,5 ± 0,4 ng/mL versus 1,1 ± 0,4 ng/mL and 0,7 ± 0,1 ng/mL versus 0,3 ± 0,1 ng/mL, resp.). Subjects with significant lesion in left anterior descending artery (LAD) had lower serum ET-1 compared to those with normal LAD (0,6 ± 0,2 pg/mL versus 0,9 ± 0,4 pg/mL). Patients with three-vessel coronary artery disease (CAD) had higher level of soluble c-kit compared to those with one- or two-vessel CAD: 19,9 ± 24,1 ng/mL versus 5,6 ± 1,9 ng/mL.

Conclusions: Elevated serum tryptase and ET-1 may be markers of increased coronary instability; some cytokines may be related to the extension of CAD.

Citing Articles

Tryptase: The Silent Witness of Past and Ongoing Systemic Events.

Ostric Pavlovic I, Radovic S, Krtinic D, Spiric J, Kusic N, Velickovic A Medicina (Kaunas). 2024; 60(9).

PMID: 39336421 PMC: 11434177. DOI: 10.3390/medicina60091380.

LncRNA MALAT1 functions as a biomarker of no-reflow phenomenon in ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention.

Yang X, Dai R, Qin Z, Cai R, Xu Y, Su Q Sci Rep. 2022; 12(1):3294.

PMID: 35228564 PMC: 8885644. DOI: 10.1038/s41598-022-06923-z.

The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis.

Yu D, Cai Y, Zhou W, Sheng J, Xu Z Dis Markers. 2018; 2018:1984718.

PMID: 29736193 PMC: 5875026. DOI: 10.1155/2018/1984718.

Mast cell derived carboxypeptidase A3 is decreased among patients with advanced coronary artery disease.

Lewicki L, Siebert J, Kolinski T, Piekarska K, Reiwer-Gostomska M, Targonski R Cardiol J. 2018; 26(6):680-686.

PMID: 29512095 PMC: 8083039. DOI: 10.5603/CJ.a2018.0018.

Effects of propofol on myocardial ischemia-reperfusion injury in rats with type-2 diabetes mellitus.

Wang Y, Qi X, Wang C, Zhao D, Wang H, Zhang J Biomed Rep. 2017; 6(1):69-74.

PMID: 28123710 PMC: 5244760. DOI: 10.3892/br.2016.805.

References

Dahlen D, Lin N, Liu Y, Broudy V . Soluble Kit receptor blocks stem cell factor bioactivity in vitro. Leuk Res. 2001; 25(5):413-21. DOI: 10.1016/s0145-2126(00)00122-3. View

Hara M, Ono K, Hwang M, Iwasaki A, Okada M, Nakatani K . Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002; 195(3):375-81. PMC: 2193589. DOI: 10.1084/jem.20002036. View

Filipiak K, Tarchalska-Krynska B, Opolski G, Rdzanek A, Kochman J, Kosior D . Tryptase levels in patients after acute coronary syndromes: the potential new marker of an unstable plaque?. Clin Cardiol. 2003; 26(8):366-72. PMC: 6654608. DOI: 10.1002/clc.4950260804. View

Kaartinen M, Penttila A, Kovanen P . Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas. Arterioscler Thromb. 1994; 14(6):966-72. DOI: 10.1161/01.atv.14.6.966. View

Kaartinen M, Penttila A, Kovanen P . Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 1994; 90(4):1669-78. DOI: 10.1161/01.cir.90.4.1669. View

Kovanen P, Kaartinen M, Paavonen T . Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995; 92(5):1084-8. DOI: 10.1161/01.cir.92.5.1084. View

Kaartinen M, Penttila A, Kovanen P . Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha. Circulation. 1996; 94(11):2787-92. DOI: 10.1161/01.cir.94.11.2787. View

Tello-Montoliu A, Patel J, Lip G . Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost. 2006; 4(9):1864-74. DOI: 10.1111/j.1538-7836.2006.01995.x. View

Lee-Rueckert M, Kovanen P . Mast cell proteases: physiological tools to study functional significance of high density lipoproteins in the initiation of reverse cholesterol transport. Atherosclerosis. 2006; 189(1):8-18. DOI: 10.1016/j.atherosclerosis.2006.02.014. View

10.

Kovanen P . Mast cells: multipotent local effector cells in atherothrombosis. Immunol Rev. 2007; 217:105-22. DOI: 10.1111/j.1600-065X.2007.00515.x. View

11.

Siebert J, Reiwer-Gostomska M, Babinska Z, Mysliwska J, Mysliwski A, SkopiNska-ROZewska E . Low serum angiogenin concentrations in patients with type 2 diabetes. Diabetes Care. 2007; 30(12):3086-7. DOI: 10.2337/dc07-0629. View

12.

Tello-Montoliu A, Marin F, Patel J, Roldan V, Mainar L, Vicente V . Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J. 2007; 28(24):3006-11. DOI: 10.1093/eurheartj/ehm488. View

13.

Siebert J, Reiwer-Gostomska M, Mysliwska J, Marek N, Raczynska K, Glasner L . Glycemic control influences serum angiogenin concentrations in patients with type 2 diabetes. Diabetes Care. 2010; 33(8):1829-30. PMC: 2909070. DOI: 10.2337/dc10-0130. View

14.

Xiang M, Sun J, Lin Y, Zhang J, Chen H, Yang D . Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population. Atherosclerosis. 2011; 215(2):494-9. PMC: 3070056. DOI: 10.1016/j.atherosclerosis.2011.01.006. View

15.

Marek N, Raczynska K, Siebert J, Mysliwiec M, Zorena K, Mysliwska J . Decreased angiogenin concentration in vitreous and serum in proliferative diabetic retinopathy. Microvasc Res. 2011; 82(1):1-5. DOI: 10.1016/j.mvr.2011.04.006. View

16.

Kolettis T, Barton M, Langleben D, Matsumura Y . Endothelin in coronary artery disease and myocardial infarction. Cardiol Rev. 2013; 21(5):249-56. DOI: 10.1097/CRD.0b013e318283f65a. View

17.

Chen J, Chen M, Guo Y, Zhu C, Xu R, Dong Q . Plasma big endothelin-1 level and the severity of new-onset stable coronary artery disease. J Atheroscler Thromb. 2014; 22(2):126-35. DOI: 10.5551/jat.26401. View

18.

Shahzad U, Li G, Zhang Y, Li R, Rao V, Yau T . Transmyocardial Revascularization Enhances Bone Marrow Stem Cell Engraftment in Infarcted Hearts Through SCF-C-kit and SDF-1-CXCR4 Signaling Axes. Stem Cell Rev Rep. 2014; 11(2):332-46. DOI: 10.1007/s12015-014-9571-7. View

19.

Heldin C . Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 2013; 11:97. PMC: 3878225. DOI: 10.1186/1478-811X-11-97. View

20.

Pastorello E, Morici N, Farioli L, Di Biase M, Losappio L, Nichelatti M . Serum tryptase: a new biomarker in patients with acute coronary syndrome?. Int Arch Allergy Immunol. 2014; 164(2):97-105. DOI: 10.1159/000360164. View